

# Human CEACAM8/CD66b Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00368 Size: 96T Sensitivity: 5.2 pg/mL Range: 46.88-3000 pg/mL Usage: For the quantitative detection of human CEACAM8/CD66b concentrations in serum, plasma and cell culture supernatant.

This product is for research use only and not for use in human or animal therapeutic or diagnostic.

ptglab.com


Table of content	pag	;e
1. Background		3
2. Principle	•••••	3
3. Required Materials		3
4. Kit Components and Storage		4
5. Safety Notes		4
6. Sample Collection and Storage		4
7. Regent Preparation		5
8. Assay Procedure Summary		6
9. Validation Data		7
9.1 Standard curve		7
9.2 Precision ••••••	•••••	7
9.3 Recovery	•••••	7
9.4 Sample values	•••••	8
9.5 Sensitivity		8
9.6 Linearity		8
9.7 Specificity		8
10. References		9

ptglab.com

#### 1. Background

A glycosylphosphatidyl-inositol-(GPI)-anchored glycoprotein, carcinoembryonic antigen (CEA)-related cell adhesion molecule 8 (CEACAM8), also known as CD66b, NCA-95 and CD67, was identified in human neutrophils. It is solely expressed by granulocytes, of which 95% are polymorphonuclear neutrophils (PMN). CEACAM8 is cell-adhesion proteins on neutrophils that belong to the human carcinoembryonic antigen (CEA) family. CEA family members are believed to function as intercellular adhesion molecules in vitro. CEACAM8 has been shown to adhere to the closely related molecule CEACAM6 (NCA-50/90 and CD66c), suggesting a role in the interaction between granulocytes or between granulocytes and epithelial cells expressing CEACAM6 in vivo.

#### 2. Principle



# Sandwich ELISA structure (Detection antibody labeled with HRP)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with HRP also binds to the analyte. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

#### 3. Required Materials

3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.

3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.

3.3 Plate washer: automated or manual.

3.4 Absorbent paper towels.

3.5 Glass or plastic tubes to prepare standard and sample dilutions.

3.6 Beakers and graduated cylinders.

3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.



# 4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	1 plate	Unopened Kit:
Protein standard - 6000 pg/bottle; lyophilized	2 bottles	
Detection antibody, HRP-conjugated (100×) - 120 µL/vial*	1 vial	Store at 2-8°C for 6 months or -
Sample Diluent PT 3 - 30 mL/bottle	1 bottle	20°C for 12 months.
Detection Diluent - 30 mL/bottle	1 bottle	Opened Kit:
Wash Buffer Concentrate (20×) - 30 mL/bottle	1 bottle	All reagents stored at 2-8°C for
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle	1 bottle	0
Stop Solution - 12 mL/bottle	1 bottle	7 days.
		Please use a new standard
Plate Cover Seals	4 pieces	for each assay.

\* Centrifugation immediately before use

#### 5. Safety Notes

5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

5.2 Do not use the kit after the expiration date.

5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.

5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.

5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

#### 6. Sample Collection and Storage

6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at  $\leq$  -20°C. Avoid repeated freeze-thaw cycles.



# 7. Regent Preparation

**7.1 Wash Buffer (1X):** If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.


**7.2 Detection Antibody, HRP-conjugated(1X):** Dilute 100X Detection Antibody, HRP-conjugated 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Detection Antibody, HRP-conjugated + 990 µL Detection Diluent (Centrifuge the 100 X Detection Antibody solution, HRP-conjugated for a few seconds prior to use).

**7.3 Sample Dilution:** Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 or 1:4 is recommended for human serum, plasma and cell culture supernatant.

#### 7.4 Standard Serial Dilution:

Add 2 mL Sample Diluent PT 3 in protein standard.



ptglab.com

#### 8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody, HRP-conjugated can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent. 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group, add 100 µL of each standard and sample to the appropriate wells. (Make sure sample addition is uninterrupted and completed within 5 to 10 minutes, It is recommended to assay all standards, controls, and samples in duplicate).

8.3 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 2 hours at 37°C.8.4 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.
Add 100 µL of 1X Detection antibody, HRP-conjugated solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 40 minutes at 37°C.

8.6 Repeat wash step in 8.4.

8.7 Signal development: Add 100 µL of TMB substrate solution to each well, protected from light. Incubate for 15 to

20 minutes. Substrate Solution should remain colorless until added to the plate.

8.8 Quenching color development: Add 100 μL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.9 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.10 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

Step	Reagent	Volume	Incubation	Wash	Notes	
1	Standard and Samples	100 µL	120 min	4 times	Cover Wells incubate at 37°C	
2	Diluent Detection antibody, HRP-conjugated Solution	100 µL	40 min	4 times	Cover Wells incubate at 37°C	
3	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C	
4	Stop Solution	100 µL	0 min	Do not wash	-	
5	Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.					

# 9. Validation Data

#### 9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(pg/mL)	0.D	Average	Corrected
0	0.0955 0.1031	0.0993	-
46.88	0.2092 0.2271	0.21815	0.11885
93.75	0.3368 0.3215	0.32915	0.22985
187.5	0.5244 0.4436	0.484	0.3847
375	0.7836 0.7422	0.7629	0.6636
750	1.26 1.2695	1.26475	1.16545
1500	1.9192 1.9557	1.93745	1.83815
3000	2.4638 2.4607	2.46225	2.36295

#### 9.2 Precision

**Intra-assay Precision** (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

**Inter-assay Precision** (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision				Inter-assay Precision						
Sample	n	Mean (pg/mL)	SD	CV%		Sample	n	Mean (pg/mL)	SD	CV%
1	20	1,597.9	72.9	4.6		1	24	1,683.8	113.4	6.7
2	20	350.9	25.1	7.2		2	24	378.7	36.6	9.7
3	20	87.7	7.0	8.0		3	24	17.8	1.8	9.9

#### 9.3 Recovery

The recovery of human CEACAM8/CD66b spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human serum	1:8	83	77-92
Cell culture supernatant	1:4	101	98-107

#### 9.4 Sample values

Serum - human serum samples were evaluated for the presence of human CEACAM8/CD66b in this assay.

Sample Type	Mean (pg/mL)	Range (pg/mL)
Human serum (n=16)	820.7	282.8-2,350.0

Cell culture supernatant - human peripheral blood mononuclear cells (1 x 10<sup>6</sup> cells/mL) were cultured in

DMEM supplemented 10% fetal bovine serum,  $5\mu$ M  $\beta$ -mercaptoethanol, 2 mM L-glutamine, 100 U/mL penicillin and 100 $\mu$ g/mL streptomycin sulfate. Cells were stimulated with 10  $\mu$ g/mL PHA. Aliquots were removed on day 3 and assayed for levels of human CEACAM8/CD66b.

Condition	Day 3 (pg/mL)
Unstimulated	4.6
Stimulated	24.0

# 9.5 Sensitivity

The minimum detectable dose of human CEACAM8/CD66b is 5.2 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.

# 9.6 Linearity

To assess the linearity of the assay, cell culture supernatant samples were spiked with high concentrations of human CEACAM8/CD66b and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay. Human serum samples were diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

		Human serum	Cell culture supernatant
1.2	Average% of Expected	100	91
1:2	Range (%)	-	90-92
1./	Average% of Expected	107	93
1:4	Range (%)	106-108	91-94
1:8	Average% of Expected	118	101
1.0	Range (%)	109-127	88-113
1:16	Average% of Expected	113	116
1.10	Range (%)	108-118	115-117

# 9.7 Specificity

This kit specifically recognizes native and recombinant human CEACAM8/CD66b.

#### 10. References

- 1.F Buchegger. et al. (1984). Int J Cancer. 33(5):643-649.
- 2.Linshu Zhao. et al. (2004). Br J Haematol. 125(5):666-673.
- 3.M Kuroki. et al. (2001). J Leukoc Biol. 70(4):543-550.
- 4.S Oikawa. et al. (1991). J Biol Chem. 266(13):7995-8001.
- 5.T Yamanka. et al. (1996). Biochem Biophys Res Commun.219(3):842-847.

